Secondary analysis of a phase 3 letermovir vs valganciclovir trial in 601 CMV D+R- kidney transplant recipients: a positive QFT-CMV result at the end of prophylaxis did not predict later CMV disease (sensitivity 8.3%, NPV 17.5%; 460 evaluable).
Secondary analysisn = 601
Limaye et al. Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients